|
|
|
|
|
13.11.26 - 05:36
|
AMD and PsiQuantum expand partnership on quantum computing infrastructure (Digitimes)
|
|
|
PsiQuantum and AMD are expanding their partnership to develop infrastructure for utility-scale, fault-tolerant quantum computers and hybrid systems combining quantum, high-performance, and AI computing. The agreement includes AMD processors, GPUs, software, and an equity investment, with potential applications in drug discovery and other industries worldwide as systems scale globally....
|
|
|
|
|
|
|
13.11.26 - 00:06
|
Can Huang′s Exit Create Chip Competition (Bloomberg)
|
|
|
Jensen Huang's departure from Nvidia is raising questions about whether rivals can chip away at the company's dominance of the AI semiconductor market. Bloomberg Intelligence analysts Robert Schiffman and Mandeep Singh say demand for AI computing remains strong, but Huang's exit could create opportunities for Broadcom, AMD, Google and others as customers look for alternatives and potentially push back on Nvidia's premium pricing. (Source: Bloomberg)...
|
|
|
12.11.26 - 23:36
|
NASDAQ100 Gewinner des Tages: AMD Aktie springt 5,86 Prozent – das Nvidia-Beben macht den Herausforderer zum Sieger (Aktiencheck)
|
|
|
Advanced Micro Devices ist der NASDAQ100 Gewinner des Tages. Die AMD Aktie steigt nach dem Rücktritt von Nvidia-Chef Jensen Huang um 5,86 Prozent auf 585,30 US-Dollar und gewinnt damit binnen vier Handelstagen rund 30 Prozent. Hinter dem Kurssprung stehen eine Hochstufung durch William Blair, ein Rekordquartal, die neuen EPYC-Prozessoren und ein Milliardeneinstieg beim KI-Börsenkandidaten Anthropic. Die Aktienanalyse zum 12. November 2026: Was den NASDAQ100 Gewinner AMD treibt – und wo die Risiken liegen....
|
|
|
|
|
|
|
|
|
12.11.26 - 22:09
|
Lineage Cell Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update (Business Wire)
|
|
|
Acquired NeuroAirmid Therapeutics, Inc. and Its Cell Therapy Product Candidate for Huntington's Disease, Currently Enrolling in a Phase 1b/2a Clinical Trial (REGEN4HD)
Announced Issuance of a Patent Covering its AlloSCOPE™ “5D” Technology, a Component of Its AlloSCOPE Cell Manufacturing Platform
Advanced Collaboration with William Demant Invest for ReSonance® Into a Second Year; Danish Medicines Agency Meeting Scheduled in Q4 2026 to Discuss Development Plans
Advanced Corneal Endothelial Disease Program (COR1) Into Preclinical Testing; Initial Data Expected in Q1 2027
OpRegen® Cell Therapy Continues to be Evaluated in Genentech's GAlette Study for the Treatment of Dry-AMD with Geographic Atrophy
Cash, Cash Equivalents, and Marketable Securities as of September 30, 2026, Expected to Support Planned Operations into Q2 2028
CARLSBAD, Calif.--(BUSINESS WIRE)--$LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company devel...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
